Rare disease pharmaceutical company QOL Medical LLC reported on Saturday that Sucraid (sacrosidase) Oral Solution has been shown to be 81% effective in the treatment of patients with Congenital Sucrase-Isomaltase Deficiency (CSID), a rare genetic condition, when used appropriately.

Eligible patients can now try Sucraid for free with a four-day trial offer through their medical provider. Testing can support a CSID diagnosis, but QOL Medical noted that other factors may cause sucrose intolerance. False positives and false negatives can occur, making clinical evaluation crucial to ensure accurate diagnosis and effective treatment for this life altering condition.

According to QOL Medical, Sucraid is specifically designed to help patients with CSID by providing the enzyme sacrosidase, which aids in breaking down sucrose.